Correction to: Cell Death and Disease (2013) 4, e796; doi:10.1038/cddis.2013.315; published online 12 September 2013
Since the publication of this paper the authors have noticed a number of errors. On page 1, second paragraph, the first sentence should read:
In this context, new Pt(II) complexes have been specifically synthesized by some of us in order to overcome the cisplatin-related problems.2,3 The ability of these new Pt(II) compounds to induce apoptosis in human cancer cells has been studied and compared with the well-established anticancer drug, cisPt; among them, [Pt(O,O′-acac)(γ-acac)(DMS)] (PtAcD) exhibited the highest in vitro activity.
On page 9, second column, the starting sentence under ‘Reagents’ should read:
Reagents
PtAcD was prepared according to previously reported procedures.3
Reference 2 has been removed and replaced by the original reference 33.
The corrected article appears online together with this corrigendum. The authors would like to apologize for any inconvenience this may have caused.
Additional information
The online version of the original article can be found at 10.1038/cddis.2013.315
Rights and permissions
About this article
Cite this article
Muscella, A., Vetrugno, C., Fanizzi, F. et al. Erratum: A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells. Cell Death Dis 5, e1388 (2014). https://doi.org/10.1038/cddis.2014.340
Published:
Issue Date:
DOI: https://doi.org/10.1038/cddis.2014.340
This article is cited by
-
Three anticancer Pt complexes with glycine derivatives: synthesis, bioactivity on MCF-7 cell line, ADME prediction, DFT, MEP, and molecular docking
Journal of the Iranian Chemical Society (2021)
